Systematic review and meta‐analysis of reported adverse events of long‐term intranasal oxytocin treatment for autism spectrum disorder
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Recent studies have suggested oxytocin as a possible drug to treat social deficits caused by autism spectrum disorder (ASD), but the safety of intranasal oxytocin in autistic patients has not been established. The aim of this review was to characterize the side‐effect profile of long‐term intranasal oxytocin in treatment of ASD compared to placebo. All randomized controlled trials of intranasal oxytocin in the treatment of ASD published before 1 January 2017 that reported safety data were identified from databases, including PubMed, Embase, Cochrane Library, and International Pharmaceutical Abstract. Relevant data from the selected studies were then extracted for meta‐analysis to estimate the pooled risk ratio for the most common adverse events. Descriptive analysis of severe adverse events was also conducted. Of the 223 participants in the five included studies, 123 were given oxytocin and 100 were given placebos. Nasal discomfort (14.3%), tiredness (7.2%), irritability (9.0%), diarrhea (4.5%), and skin irritation (4.5%) were the most common adverse events. None of these common adverse events was statistically associated with treatment allocation according to meta‐analysis using pooled data (all P‐values > 0.1). Five severe adverse events were reported, namely aggression (one in placebo, two in oxytocin) and seizures (one in placebo, one in oxytocin). Results from this systematic review support intranasal oxytocin as well tolerated and safe for use in the ASD population. Larger clinical trials should be conducted to establish the efficacy of intranasal oxytocin as a treatment of ASD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hofmann, S. G., Fang, A., & Brager, D. N. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.05.039 · Cited by 44
RetractedOxytocin shapes the neural circuitry of trust and trust adaptation in humans
Baumgartner, T., Heinrichs, M., Vonlanthen, A., Fischbacher, U., & Fehr, E. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.009 · Cited by 1,258
Promoting social behavior with oxytocin in high-functioning autism spectrum disorders.
Andari, E., Duhamel, J.-R., Zalla, T., Herbrecht, E., Leboyer, M., & Sirigu, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910249107 · Cited by 941
The Neurobiology of Human Attachments
Feldman, R. (2017) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2016.11.007 · Cited by 839 · cited 1×
“Oxytocin is associated with various physiological and neurological processes, but in the context of ASD, oxytocin’s ability to mediate the formation of bonds between individuals is the most relevant.(6) Given oxytocin’s role in influencing social behavior, it is possible that ASD is linked to an individual’s inability…”
BackgroundStriepens, N., Kendrick, K. M., Hanking, V., Landgraf, R., Wüllner, U., Maier, W., & Hurlemann, R. (2013) · Scientific Reports · doi:10.1038/srep03440 · Cited by 452
Guastella, A. J., Hickie, I. B., McGuinness, M. M., Otis, M., Woods, E. A., Disinger, H. M., Chan, H.-K., Chen, T. F., & Banati, R. B. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.11.019 · Cited by 357
Anagnostou, E., Soorya, L., Chaplin, W., Bartz, J., Halpern, D., Wasserman, S., Wang, A. T., Pepa, L., Tanel, N., Kushki, A., et al. (2012) · Molecular Autism · doi:10.1186/2040-2392-3-16 · Cited by 350
Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.162 · Cited by 344 · cited 10×
“However, the study by Yatawara et al.(82) only stated the total number of adverse events without providing detailed breakdown for each type of adverse event separately.”
BackgroundMethodInfluentialIntranasal Treatment of Central Nervous System Dysfunction in Humans
Chapman, C. D., Frey, W. H., Craft, S., Danielyan, L., Hallschmid, M., Schiöth, H. B., & Benedict, C. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0915-1 · Cited by 310
Guastella, A. J., Gray, K. M., Rinehart, N. J., Alvares, G. A., Tonge, B. J., Hickie, I. B., Keating, C. M., Cacciotti‐Saija, C., & Einfeld, S. L. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12305 · Cited by 299 · cited 4×
“Selection bias Guastella et al.(83) and Yatawara et al.”
BackgroundInfluentialBales, K. L., Perkeybile, A. M., Conley, O. G., Lee, M. H., Guoynes, C. D., Downing, G. M., Yun, C. R., Solomon, M., Jacob, S., & Mendoza, S. P. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.025 · Cited by 265
Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder
Domes, G., Heinrichs, M., Kumbier, E., Grossmann, A., Hauenstein, K., & Herpertz, S. C. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.007 · Cited by 255
Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial
Dadds, M. R., MacDonald, E., Cauchi, A., Williams, K., Levy, F., & Brennan, J. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1899-3 · Cited by 250
Auyeung, B., Lombardo, M. V., Heinrichs, M., Chakrabarti, B., Sule, A., Deakin, J. B., Bethlehem, R. A. I., Dickens, L., Mooney, N., Sipple, J. A. N., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2014.146 · Cited by 234
Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism
Watanabe, T., Kuroda, M., Kuwabara, H., Aoki, Y., Iwashiro, N., Tatsunobu, N., Takao, H., Nippashi, Y., Kawakubo, Y., Kunimatsu, A., et al. (2015) · Brain · doi:10.1093/brain/awv249 · Cited by 222
Chronic and acute intranasal oxytocin produce divergent social effects in mice
Huang, H., Michetti, C., Busnelli, M., Managò, F., Sannino, S., Scheggia, D., Giancardo, L., Sona, D., Murino, V., Chini, B., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.310 · Cited by 199
Meta-analysis of the effects of intranasal oxytocin on interpretation and expression of emotions
Leppanen, J., Ng, K. W., Tchanturia, K., & Treasure, J. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.010 · Cited by 188
Oxytocin improves behavioural and neural deficits in inferring others’ social emotions in autism
Aoki, Y., Yahata, N., Watanabe, T., Takano, Y., Kawakubo, Y., Kuwabara, H., Iwashiro, N., Natsubori, T., Inoue, H., Suga, M., et al. (2014) · Brain · doi:10.1093/brain/awu231 · Cited by 187
Paloyelis, Y., Doyle, O. M., Zelaya, F. O., Maltezos, S., Williams, S. C., Fotopoulou, A., & Howard, M. A. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.10.005 · Cited by 187
Watanabe, T., Abe, O., Kuwabara, H., Yahata, N., Takano, Y., Iwashiro, N., Natsubori, T., Aoki, Y., Takao, H., Kawakubo, Y., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3181 · Cited by 183
Switching brain serotonin with oxytocin
Mottolese, R., Redouté, J., Costes, N., Le Bars, D., & Sirigu, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319810111 · Cited by 179
Cardoso, C., Kingdon, D., & Ellenbogen, M. A. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.07.014 · Cited by 171
Scheele, D., Kendrick, K. M., Khouri, C., Kretzer, E., Schläpfer, T. E., Stoffel-Wagner, B., Güntürkün, O., Maier, W., & Hurlemann, R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.78 · Cited by 171
Domes, G., Kumbier, E., Heinrichs, M., & Herpertz, S. C. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.254 · Cited by 160
Feng, C., Hackett, P. D., DeMarco, A. C., Chen, X., Stair, S., Haroon, E., Ditzen, B., Pagnoni, G., & Rilling, J. K. (2015) · Brain Imaging and Behavior · doi:10.1007/s11682-014-9333-9 · Cited by 157
Anagnostou, E., Soorya, L., Brian, J., Dupuis, A., Mankad, D., Smile, S., & Jacob, S. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.049 · Cited by 155
Tachibana, M., Kagitani-Shimono, K., Mohri, I., Yamamoto, T., Sanefuji, W., Nakamura, A., Oishi, M., Kimura, T., Onaka, T., Ozono, K., et al. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0048 · Cited by 151
Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome
Hall, S. S., Lightbody, A. A., McCarthy, B. E., Parker, K. J., & Reiss, A. L. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.07.020 · Cited by 143
Developmental experiences and the oxytocin receptor system
Bales, K. L., & Perkeybile, A. M. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.12.013 · Cited by 142
Intranasal oxytocin selectively attenuates rhesus monkeys’ attention to negative facial expressions
Parr, L. A., Modi, M., Siebert, E., & Young, L. J. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.02.011 · Cited by 124
Intranasal oxytocin administration is reflected in human saliva
Weisman, O., Zagoory-Sharon, O., & Feldman, R. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.02.014 · Cited by 120 · cited 1×
“The biological halflife of oxytocin had been found to be around 2 h.(87) Therefore, for these crossover trials, it was deemed that a washout period was unnecessary due to limited carryover effects.”
BackgroundKosaka, H., Okamoto, Y., Munesue, T., Yamasue, H., Inohara, K., Fujioka, T., Anme, T., Orisaka, M., Ishitobi, M., Jung, M., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.152 · Cited by 117 · cited 7×
“Kosaka et al.85 did not include participants diagnosed with Asperger’s syndrome.”
BackgroundMethodResultInfluentialGordon, I., Jack, A., Pretzsch, C. M., Vander Wyk, B., Leckman, J. F., Feldman, R., & Pelphrey, K. A. (2016) · Scientific Reports · doi:10.1038/srep35054 · Cited by 114
Intranasal oxytocin enhances intrinsic corticostriatal functional connectivity in women
Bethlehem, R. A. I., Lombardo, M. V., Lai, M.-C., Auyeung, B., Crockford, S. K., Deakin, J., Soubramanian, S., Sule, A., Kundu, P., Voon, V, et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.72 · Cited by 96
Aoki, Y., Watanabe, T., Abe, O., Kuwabara, H., Yahata, N., Takano, Y., Iwashiro, N., Natsubori, T., Takao, H., Kawakubo, Y., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.74 · Cited by 95
Alvares, G. A., Quintana, D. S., & Whitehouse, A. J. O. (2017) · Autism Research · doi:10.1002/aur.1692 · Cited by 91 · cited 1×
“, number of participants) and experimental design.(8) Before considering larger-scale trials and clinical applications of intranasal oxytocin in ASD patients, it is important for us to establish the safety of intranasal oxytocin in the ASD population.”
BackgroundMunesue, T., Nakamura, H., Kikuchi, M., Miura, Y., Takeuchi, N., Anme, T., Nanba, E., Adachi, K., Tsubouchi, K., Sai, Y., et al. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00002 · Cited by 84 · cited 3×
“Munesue et al.(86) reported seizures in two participants.”
BackgroundInfluentialRestoring effects of oxytocin on the attentional preference for faces in autism
Kanat, M., Spenthof, I., Riedel, A., van Elst, L. T., Heinrichs, M., & Domes, G. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.67 · Cited by 70
Long-term oxytocin administration improves social behaviors in a girl with autistic disorder
Kosaka, H., Munesue, T., Ishitobi, M., Asano, M., Omori, M., Sato, M., Tomoda, A., & Wada, Y. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-110 · Cited by 65
Adaptive coding of the value of social cues with oxytocin, an fMRI study in autism spectrum disorder
Andari, E., Richard, N., Leboyer, M., & Sirigu, A. (2016) · Cortex · doi:10.1016/j.cortex.2015.12.010 · Cited by 62
Effects of a 10-day oxytocin trial in older adults on health and well-being
Barraza, J. A., Grewal, N. S., Ropacki, S., Perez, P., Gonzalez, A., & Zak, P. J. (2013) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0031581 · Cited by 61
Genetic modulation of oxytocin sensitivity: A pharmacogenetic approach
Chen, F. S., Kumsta, R., Dvorak, F., Domes, G., Yim, O. S., Ebstein, R. P., & Heinrichs, M. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.163 · Cited by 59
Hopf, K. P., Madren, E., & Santianni, K. A. (2016) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2015.0163 · Cited by 58
Althaus, M., Groen, Y., Wijers, A. A., Noltes, H., Tucha, O., & Hoekstra, P. J. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.10.025 · Cited by 57
Oxytocin receptor gene variations predict neural and behavioral response to oxytocin in autism
Watanabe, T., Otowa, T., Abe, O., Kuwabara, H., Aoki, Y., Natsubori, T., Takao, H., Kakiuchi, C., Kondo, K., Ikeda, M., et al. (2017) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsw150 · Cited by 54 · cited 1×
“Based on full text review of the remaining 12 studies, five were rejected for being short-term studies (less than a month), while one was rejected for not being a randomized controlled trial.(80) The rejected studies are presented in Table S1.”
BackgroundLin, I.-F., Kashino, M., Ohta, H., Yamada, T., Tani, M., Watanabe, H., Kanai, C., Ohno, T., Takayama, Y., Iwanami, A., et al. (2014) · Molecular Autism · doi:10.1186/2040-2392-5-20 · Cited by 40
The Potential of Nasal Oxytocin Administration for Remediation of Autism Spectrum Disorders
Okamoto, Y., Ishitobi, M., Wada, Y., & Kosaka, H. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160413120845 · Cited by 33
Montag, C., Sauer, C., Reuter, M., & Kirsch, P. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0452-x · Cited by 32
Preckel, K., Kanske, P., Singer, T., Paulus, F. M., & Krach, S. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1036-x · Cited by 25
Cited by
Autism Spectrum Disorder: Classification, diagnosis and therapy
Sharma, S. R., Gonda, X., & Tarazi, F. I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.007 · Cited by 673
Benevides, T. W., Shore, S. M., Palmer, K., Duncan, P., Plank, A., Andresen, M.-L., Caplan, R., Cook, B., Gassner, D., Hector, B. L., et al. (2020) · Autism · doi:10.1177/1362361320908410 · Cited by 258
“Although most other fields would consider adverse effects in any intervention (medical, social-behavioral, other), autism research rarely describes adverse events with the exception of pharmacological research involving children (e.g. Cai et al., 2018).”
BackgroundVascular RAGE transports oxytocin into the brain to elicit its maternal bonding behaviour in mice
Yamamoto, Y., Liang, M., Munesue, S., Deguchi, K., Harashima, A., Furuhara, K., Yuhi, T., Zhong, J., Akther, S., Goto, H., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0325-6 · Cited by 171
Bitsika, V., & Sharpley, C. F. (2024) · Advances in Neurodevelopmental Disorders · doi:10.1007/s41252-023-00364-z · Cited by 5
“…and meta-analysis on the adverse events (i.e., side effects) associated with long-term intranasal oxytocin treatment in autistic participants, Cai et al. (2018) analysed findings from five randomised controlled trials (total participants = 223; intranasal oxytocin group = 123; placebo group…”
Metadata
- Authors
- Cai, Q., Feng, L., & Yap, K. Z.
- Venue
- Psychiatry and Clinical Neurosciences
- Publisher
- Wiley
- Published
- 2018-01-30
- Volume
- 72
- Issue
- 3
- Pages
- 140-151
- ISSN
- 1323-1316 (ISSN-L)
- 1440-1819
- OpenAlex
- W2775424805
- Cited by
- 78
- References
- 49
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.